In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong activity against the Measles virus in both cell culture studies and a humanized animal model [1] - The treatment with NV-387 resulted in the protection of lungs, which is crucial for the survival of severely ill patients during late-stage viral infections [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE Amer under the ticker NNVC [1] - The company is focused on developing antiviral therapies, with NV-387 being a significant part of its clinical pipeline [1]